Literature DB >> 22266186

Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors.

Yan Li1, Xu Li, Guangyu Fan, Jun-Ichi Fukushi, Yoshihiro Matsumoto, Yukihide Iwamoto, Yue Zhu.   

Abstract

The chromosomal translocation t(11;22)(q24;q12) yields the EWS-Fli1 fusion gene, which contributes to the development of Ewing Family Tumors (EFTs). Previous studies have shown the ability of EWS-Fli1 chimeric protein to silence p53 activity. Here we demonstrate that the introduction of EWS-Fli1 significantly inhibited p300-mediated acetylation of p53 at Lys-382 and depletion of EWS-Fli1 protein by small interfering RNAs (siRNA) in EFTs cells facilitated it in response to DNA damage. Furthermore, the deacetylation of p53 by EWS-Fli1 suppressed its transcriptional activity and enhanced mdm2-mediated p53 degradation. On the other hand, immunoprecipitation study shows that N-terminal region of EWS-Fli1 associated with histone deacetylase 1 (HDAC1) to forms a complex with p53. Knockdown of HDAC1, but not HDAC2 or HDAC3 protein restored the expression of p53 Lys-382 in EFTs cells. Overexpression of HDAC1 also significantly inhibited p53 transcriptional activity. Pharmacologic inhibitor of HDAC, trichostatin A (TSA) promoted p53-p300 interaction and recruitment of p53 Lys-382 to promoter regions of its target genes p21 and Puma, consequently inducing apoptosis and stabilizing the acetylation of p53 at Lys-382 together with the upregulation of p21 and Puma, which were impaired in EFTs cells after the knockdown of p53 expression. Our data indicate EWS-Fli1 might deacetylate p53 to inhibit its transcriptional function and protein stability via the recruitment of HDAC1. These results might elucidate a novel molecular mechanism about the abrogation of p53 pathway by EWS-Fli1 in EFTs pathogenesis.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22266186     DOI: 10.1016/j.canlet.2012.01.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  12 in total

Review 1.  Molecular mechanisms of ETS transcription factor-mediated tumorigenesis.

Authors:  Adwitiya Kar; Arthur Gutierrez-Hartmann
Journal:  Crit Rev Biochem Mol Biol       Date:  2013-09-25       Impact factor: 8.250

Review 2.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

3.  Targeted polytherapy in small cell sarcoma and its association with doxorubicin.

Authors:  S N Dumont; D Yang; A G Dumont; D Reynoso; J-Y Blay; J C Trent
Journal:  Mol Oncol       Date:  2014-06-10       Impact factor: 6.603

Review 4.  Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer.

Authors:  Sabnam Parbin; Swayamsiddha Kar; Arunima Shilpi; Dipta Sengupta; Moonmoon Deb; Sandip Kumar Rath; Samir Kumar Patra
Journal:  J Histochem Cytochem       Date:  2013-09-18       Impact factor: 2.479

Review 5.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

6.  EWS-FLI1 employs an E2F switch to drive target gene expression.

Authors:  Raphaela Schwentner; Theodore Papamarkou; Maximilian O Kauer; Vassilios Stathopoulos; Fan Yang; Sven Bilke; Paul S Meltzer; Mark Girolami; Heinrich Kovar
Journal:  Nucleic Acids Res       Date:  2015-02-20       Impact factor: 16.971

Review 7.  Prospects and challenges for the development of new therapies for Ewing sarcoma.

Authors:  Patrick J Grohar; Lee J Helman
Journal:  Pharmacol Ther       Date:  2012-10-18       Impact factor: 12.310

8.  Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.

Authors:  D N T Aryee; S Niedan; J Ban; R Schwentner; K Muehlbacher; M Kauer; R Kofler; H Kovar
Journal:  Br J Cancer       Date:  2013-10-15       Impact factor: 7.640

Review 9.  The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Authors:  Santiago Rello-Varona; David Herrero-Martín; Laura Lagares-Tena; Roser López-Alemany; Núria Mulet-Margalef; Juan Huertas-Martínez; Silvia Garcia-Monclús; Xavier García Del Muro; Cristina Muñoz-Pinedo; Oscar Martínez Tirado
Journal:  Front Oncol       Date:  2015-04-07       Impact factor: 6.244

10.  MN1-Fli1 oncofusion transforms murine hematopoietic progenitor cells into acute megakaryoblastic leukemia cells.

Authors:  D V Wenge; E Felipe-Fumero; L Angenendt; C Schliemann; E Schmidt; L H Schmidt; C Thiede; G Ehninger; W E Berdel; M-F Arteaga; J-H Mikesch
Journal:  Oncogenesis       Date:  2015-12-21       Impact factor: 7.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.